A HIGHLY SENSITIVE QUANTITATIVE BIOASSAY FOR HUMAN INTERLEUKIN-11

被引:25
作者
LU, ZY
ZHANG, XG
GU, ZJ
YASUKAWA, K
AMIOT, M
ETRILLARD, M
BATAILLE, R
KLEIN, B
机构
[1] CNRS,INST MOLEC GENET,F-34033 MONTPELLIER,FRANCE
[2] SUZHOU MED COLL,SUZHOU 215007,PEOPLES R CHINA
[3] TOSOH CORP,BIOTECHNOL RES LAB,AYASE,KANAGAWA 252,JAPAN
[4] INST BIOL,ONCOGENESE LAB,F-44035 NANTES,FRANCE
关键词
IL-11; IL-6; CYTOKINE;
D O I
10.1016/0022-1759(94)90278-X
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Human interleukin-11 (IL-11) is a cytokine with a broad spectrum of activity, similar to interleukin-6 (IL-6). However, its role in human disease is poorly understood, partly because of a lack of sensitive bioassays. A subclone (B9-11) obtained from the B9 hybridoma (which responds poorly to human IL-11) enabled us to develop a highly sensitive bioassay for human IL-11. B9-11 cells responded only to human IL-11 and IL-6 and not to other human cytokines using the same gp130 transducer chain (ciliary neurotrophic factor, leukemia inhibitory factor and oncostatin M) or to other human interleukins (interleukin-1 to interleukin-13), human hematopoietic cytokines (granulocyte colony stimulating factor, granulocyte-macrophage colony stimulating factor, colony stimulating factor-1) and various other human cytokines (interferon-alpha, tumor necrosis factor-alpha, tumor necrosis factor-beta, fibroblast growth factor and nerve growth factor). In addition, these cytokines did not interfere with the IL-11 response of B9-11 cells. IL-11-induced proliferation of B9-11 cells was unaffected by anti-murine IL-6 receptor mAb but inhibited by anti-gp130 mAb. Half-maximal proliferation of B9-11 cells was obtained with 30 pg/ml of recombinant IL-11, a concentration 300-fold lower than IL-11 concentrations known to be active on human cells. Finally, culturing of B9-11 cells with an anti-IL-6 mAb enabled us to measure the natural IL-11 produced by various cell lines. Thus, B9-11 cells should be useful for studies of IL-11 involvement in various human diseases as well as for a better understanding of the mechanisms of action of this cytokine.
引用
收藏
页码:19 / 26
页数:8
相关论文
共 15 条
[1]  
ANDERSON KC, 1992, BLOOD, V80, P2797
[2]  
BAUMANN H, 1991, J BIOL CHEM, V266, P20424
[3]  
BURGER R, 1993, J IMMUNOL METHODS, V160, P277
[4]   LEUKEMIA INHIBITORY FACTOR RECEPTOR IS STRUCTURALLY RELATED TO THE IL-6 SIGNAL TRANSDUCER, GP130 [J].
GEARING, DP ;
THUT, CJ ;
VANDENBOS, T ;
GIMPEL, SD ;
DELANEY, PB ;
KING, J ;
PRICE, V ;
COSMAN, D ;
BECKMANN, MP .
EMBO JOURNAL, 1991, 10 (10) :2839-2848
[5]   FUNCTIONAL DISCRIMINATION BETWEEN INTERLEUKIN-6 AND INTERLEUKIN-1 [J].
HELLE, M ;
BOEIJE, L ;
AARDEN, LA .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1988, 18 (10) :1535-1540
[6]   BIOLOGICAL AND CLINICAL ASPECTS OF INTERLEUKIN-6 [J].
HIRANO, T ;
AKIRA, S ;
TAGA, T ;
KISHIMOTO, T .
IMMUNOLOGY TODAY, 1990, 11 (12) :443-449
[7]   CNTF AND LIF ACT ON NEURONAL CELLS VIA SHARED SIGNALING PATHWAYS THAT INVOLVE THE IL-6 SIGNAL TRANSDUCING RECEPTOR COMPONENT GP130 [J].
IP, NY ;
NYE, SH ;
BOULTON, TG ;
DAVIS, S ;
TAGA, T ;
LI, YP ;
BIRREN, SJ ;
YASUKAWA, K ;
KISHIMOTO, T ;
ANDERSON, DJ ;
STAHL, N ;
YANCOPOULOS, GD .
CELL, 1992, 69 (07) :1121-1132
[8]   MOLECULAR-CLONING OF A CDNA-ENCODING INTERLEUKIN-11, A STROMAL CELL-DERIVED LYMPHOPOIETIC AND HEMATOPOIETIC CYTOKINE [J].
PAUL, SR ;
BENNETT, F ;
CALVETTI, JA ;
KELLEHER, K ;
WOOD, CR ;
OHARA, RM ;
LEARY, AC ;
SIBLEY, B ;
CLARK, SC ;
WILLIAMS, DA ;
YANG, YC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (19) :7512-7516
[9]  
PAUL SR, 1991, BLOOD, V77, P1723
[10]   PERSPECTIVES - INTERLEUKIN-6 - AN OSTEOTROPIC FACTOR [J].
ROODMAN, GD .
JOURNAL OF BONE AND MINERAL RESEARCH, 1992, 7 (05) :475-478